Dossier assessment
Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Risankizumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adults with moderately to severely active ulcerative colitis
Result of dossier assessment:
- Patients who have had an inadequate response to, lost response to, or were intolerant to conventional therapy: added benefit not proven
- Patients who have had an inadequate response to, lost response to, or were intolerant to a biologic therapy: added benefit not proven
Project details
- Project no.
- A24-84
- Commission
- Commission awarded on 20.08.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A24-84_en
Connected Projects
-
Dossier assessment
Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed